Drug class
Interleukin-17A Antagonist
Mechanism of action
Interleukin-17A Antagonists [MoA]
General use cases
- Psoriasis
- patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- adult patients with active psoriatic arthritis
- adult patients with active ankylosing spondylitis
- adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
